Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genelabs Technologies |
---|---|
Information provided by: | Genelabs Technologies |
ClinicalTrials.gov Identifier: | NCT00037128 |
Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug meant to enhance DHEA levels. This study is designed to evaluate both the safety and efficacy of GL701 in male lupus patients.
Condition | Intervention | Phase |
---|---|---|
Systemic Lupus Erythematosus |
Drug: GL701 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Study ID Numbers: | GL97-01 |
Study First Received: | May 15, 2002 |
ClinicalTrials.gov Identifier: | NCT00037128 |
Health Authority: | Unspecified |
Lupus SLE DHEA GL701 |
Autoimmune Diseases Lupus Erythematosus, Systemic Connective Tissue Diseases Dehydroepiandrosterone |
Immune System Diseases |